LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

Search

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

74.32 2.27

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

71.58

Max

75.6

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-100M

-229M

Pardavimai

46M

203M

Pelno marža

-112.808

Darbuotojai

1,402

EBITDA

4.7B

4.6B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+33.69% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-2B

12B

Ankstesnė atidarymo kaina

72.05

Ankstesnė uždarymo kaina

74.32

Naujienos nuotaikos

By Acuity

50%

50%

167 / 350 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-26 23:43; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Uncertainty Over Iran Peace Talks -- Market Talk

2026-03-26 23:36; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Rises Amid Signs of Easing Middle East Tensions -- Market Talk

2026-03-26 23:35; UTC

Įsigijimai, susijungimai, perėmimai

Pernod Ricard: Confirms Discussions With Brown-Forman

2026-03-26 23:29; UTC

Uždarbis

Haier Smart Home: Company to Finance Share Buybacks Via Internal Funds >600690.SH

2026-03-26 23:28; UTC

Uždarbis

Haier Smart Home Plans A Share Buybacks of CNY3.0B-CNY6.0B >600690.SH

2026-03-26 23:28; UTC

Uždarbis

Haier Smart Home Plans to Increase Payout Ratio to 60% for 2027, 2028 >600690.SH

2026-03-26 23:28; UTC

Uždarbis

Haier Smart Home Plans Cash Dividend Payout Ratio of Up to 58% for 2026 >600690.SH

2026-03-26 23:27; UTC

Uždarbis

Haier Smart Home 2025 Net CNY19.55B Vs. Net CNY18.73B >600690.SH

2026-03-26 23:27; UTC

Uždarbis

Haier Smart Home 2025 Rev CNY302.33B Vs. CNY286.01B >600690.SH

2026-03-26 23:08; UTC

Rinkos pokalbiai

Infratil's Investor Day Addresses Data-Center Issues -- Market Talk

2026-03-26 23:04; UTC

Įsigijimai, susijungimai, perėmimai

Pernod Ricard in Talks to Combine With Jack Daniel's Maker Brown-Forman -- WSJ

2026-03-26 23:04; UTC

Įsigijimai, susijungimai, perėmimai

Families Behind Pernod, Brown-Forman Would Each Likely Retain Significant Stakes, Source Says -- WSJ

2026-03-26 23:04; UTC

Įsigijimai, susijungimai, perėmimai

Pernod, Brown-Forman Discussing Mostly Stock Deal, Source Says -- WSJ

2026-03-26 23:04; UTC

Įsigijimai, susijungimai, perėmimai

Pernod-Brown-Forman Deal Announcement Could Be Weeks Away, Sources Say -- WSJ

2026-03-26 23:04; UTC

Įsigijimai, susijungimai, perėmimai

Pernod in Deal Talks With Brown-Forman -- WSJ

2026-03-26 22:41; UTC

Įsigijimai, susijungimai, perėmimai

Brown-Forman: No Agreement Has Been Reached as to Terms of Any Possible Pernod Ricard Transaction

2026-03-26 22:41; UTC

Įsigijimai, susijungimai, perėmimai

Brown-Forman: Synergies From Contemplated Pernod Ricard Combination Expected to Be Significant

2026-03-26 22:26; UTC

Uždarbis

Jiangxi Copper 2025 Rev CNY544.62B Vs. CNY516.61B >0358.HK

2026-03-26 22:26; UTC

Uždarbis

Jiangxi Copper 2025 Net CNY7.13B Vs. Net CNY6.96B >0358.HK

2026-03-26 22:26; UTC

Uždarbis

Jiangxi Copper Higher Demand For Products Supported Results>0358.HK

2026-03-26 22:08; UTC

Uždarbis

Air China 2025 Loss CNY1.79B Vs. Loss CNY232.56M >0753.HK

2026-03-26 22:08; UTC

Uždarbis

Air China Impairment Loss on Goodwill Weighed on Results>0753.HK

2026-03-26 22:08; UTC

Uždarbis

Air China 2025 Rev CNY171.48B Vs. CNY166.70B >0753.HK

2026-03-26 22:07; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Global Energy Roundup: Market Talk

2026-03-26 22:07; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Open-Pit Gold Miners Most Exposed to High Fuel Prices -- Market Talk

2026-03-26 22:00; UTC

Uždarbis

Tsingtao Brewery 2025 Net CNY4.59B Vs. Net CNY4.34B >0168.HK

2026-03-26 22:00; UTC

Uždarbis

Tsingtao Brewery: Higher Volume Sales of Beer Supported Results>0168.HK

2026-03-26 22:00; UTC

Uždarbis

Tsingtao Brewery 2025 Rev CNY32.47B Vs. CNY32.14B >0168.HK

2026-03-26 21:39; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope: Sees Early Indications of Strong Interest in Site Adjacent Western Port

2026-03-26 21:38; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope: Has Begun Expression of Interest Process For 65-Hectare Site Adjacent Western Port

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

33.69% į viršų

12 mėnesių prognozė

Vidutinis 97.19 USD  33.69%

Aukščiausias 120 USD

Žemiausias 72 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

14 ratings

11

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

167 / 350 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat